PAVM 250117 7.50C (PAVM250117C7500) Stock Options, News & Quotes

0.05
0.000.00%

15min DelayClose Dec 24 13:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Dec 23 07:03

NEWS

$PAVmed (PAVM.US)$ $Lucid Diagnostics (LUCD.US)$
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Monday, 23rd December at 8:01 am
NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced that it had received written notification from the Listing Qualifications Depart...

Jaguar8

Dec 11 07:21

NEWS

$Lucid Diagnostics (LUCD.US)$ $PAVmed (PAVM.US)$
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
Wednesday, 11th December at 8:01 am
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing
NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or...

Trytosaveabit

Dec 11 07:03

Update

$PAVmed (PAVM.US)$ Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
2 MINUTES AGO, 8:01 AM EST
VIA PR NEWSWIRE
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing

Trytosaveabit

Nov 20 06:58

Update

$PAVmed (PAVM.US)$ $Lucid Diagnostics (LUCD.US)$ Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test
PR Newswire· 2 mins ago
NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.(Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its Eso...

Jaguar8

Oct 10 06:52

NEWS

$PAVmed (PAVM.US)$
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
PAVmed's subsidiary, Veris Health, has been awarded a $1.8 million grant from the National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH). The two-year grant will fund research to optimize and validate the Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center.
The ...